Acurian, Inc. Announces Its Contribution of Over 600 Randomized Patients in Global, Phase III Diabetes Trial at Therapeutic Conference in Amsterdam
1/27/2011 10:35:25 AM
AMSTERDAM--(BUSINESS WIRE)--Acurian, Inc., a leading, full-service provider of patient recruitment and retention solutions, announced today at the Patient Recruitment & Retention for Diabetes & Obesity Studies Conference in Amsterdam that it recently completed its enrollment contribution of over 600 diabetes patients for a global, nine-protocol diabetes study.
comments powered by